Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/07/26 | 914 | 950 | 906 | 932 | +18 | +2% | 22,200 |
| 2024/07/25 | 918 | 926 | 901 | 914 | -7 | -0.8% | 39,800 |
| 2024/07/24 | 942 | 957 | 918 | 921 | -19 | -2% | 25,800 |
| 2024/07/23 | 933 | 946 | 917 | 940 | +7 | +0.8% | 43,200 |
| 2024/07/22 | 962 | 975 | 933 | 933 | -38 | -3.9% | 61,000 |
| 2024/07/19 | 975 | 992 | 963 | 971 | +1 | +0.1% | 40,500 |
| 2024/07/18 | 1,050 | 1,050 | 960 | 970 | -60 | -5.8% | 173,700 |
| 2024/07/17 | 998 | 1,063 | 993 | 1,030 | +36 | +3.6% | 100,500 |
| 2024/07/16 | 1,011 | 1,015 | 984 | 994 | -18 | -1.8% | 48,200 |
| 2024/07/12 | 982 | 1,032 | 981 | 1,012 | +12 | +1.2% | 50,600 |
| 2024/07/11 | 1,001 | 1,015 | 975 | 1,000 | ±0 | ±0% | 53,000 |
| 2024/07/10 | 1,007 | 1,024 | 991 | 1,000 | +16 | +1.6% | 54,700 |
| 2024/07/09 | 1,002 | 1,004 | 980 | 984 | -27 | -2.7% | 30,900 |
| 2024/07/08 | 1,020 | 1,032 | 954 | 1,011 | -9 | -0.9% | 113,500 |
| 2024/07/05 | 1,010 | 1,020 | 1,001 | 1,020 | +17 | +1.7% | 22,700 |
| 2024/07/04 | 1,012 | 1,055 | 1,002 | 1,003 | +1 | +0.1% | 71,700 |
| 2024/07/03 | 1,022 | 1,030 | 1,000 | 1,002 | -14 | -1.4% | 60,900 |
| 2024/07/02 | 1,051 | 1,053 | 1,005 | 1,016 | -35 | -3.3% | 81,800 |
| 2024/07/01 | 1,090 | 1,090 | 1,020 | 1,051 | -47 | -4.3% | 100,000 |
| 2024/06/28 | 1,210 | 1,210 | 1,088 | 1,098 | -102 | -8.5% | 159,200 |
| 2024/06/27 | 1,161 | 1,223 | 1,147 | 1,200 | +43 | +3.7% | 85,900 |
| 2024/06/26 | 1,185 | 1,215 | 1,150 | 1,157 | -15 | -1.3% | 59,200 |
| 2024/06/25 | 1,155 | 1,200 | 1,137 | 1,172 | +20 | +1.7% | 31,600 |
| 2024/06/24 | 1,187 | 1,198 | 1,152 | 1,152 | -16 | -1.4% | 38,100 |
| 2024/06/21 | 1,080 | 1,225 | 1,080 | 1,168 | +88 | +8.1% | 122,000 |
| 2024/06/20 | 1,178 | 1,236 | 1,072 | 1,080 | -40 | -3.6% | 115,100 |
| 2024/06/19 | 1,125 | 1,125 | 1,099 | 1,120 | +1 | +0.1% | 14,000 |
| 2024/06/18 | 1,140 | 1,140 | 1,103 | 1,119 | -22 | -1.9% | 11,100 |
| 2024/06/17 | 1,113 | 1,141 | 1,096 | 1,141 | +28 | +2.5% | 5,000 |
| 2024/06/14 | 1,138 | 1,150 | 1,098 | 1,113 | -55 | -4.7% | 22,100 |
| 2024/06/13 | 1,173 | 1,208 | 1,131 | 1,168 | +25 | +2.2% | 29,800 |
| 2024/06/12 | 1,165 | 1,191 | 1,129 | 1,143 | -22 | -1.9% | 10,200 |
| 2024/06/11 | 1,119 | 1,180 | 1,118 | 1,165 | +66 | +6% | 30,100 |
| 2024/06/10 | 1,054 | 1,115 | 1,053 | 1,099 | +34 | +3.2% | 22,600 |
| 2024/06/07 | 1,141 | 1,141 | 1,039 | 1,065 | -77 | -6.7% | 38,600 |
| 2024/06/06 | 1,188 | 1,199 | 1,111 | 1,142 | -42 | -3.5% | 23,800 |
| 2024/06/05 | 1,152 | 1,219 | 1,152 | 1,184 | +25 | +2.2% | 24,200 |
| 2024/06/04 | 1,125 | 1,183 | 1,125 | 1,159 | +49 | +4.4% | 21,400 |
| 2024/06/03 | 1,154 | 1,154 | 1,107 | 1,110 | -42 | -3.6% | 14,300 |
| 2024/05/31 | 1,108 | 1,152 | 1,097 | 1,152 | +44 | +4% | 13,900 |
| 2024/05/30 | 1,150 | 1,150 | 1,088 | 1,108 | -53 | -4.6% | 37,300 |
| 2024/05/29 | 1,174 | 1,211 | 1,130 | 1,161 | -1 | -0.1% | 33,400 |
| 2024/05/28 | 1,080 | 1,235 | 1,074 | 1,162 | +74 | +6.8% | 76,700 |
| 2024/05/27 | 1,050 | 1,102 | 1,046 | 1,088 | +51 | +4.9% | 23,500 |
| 2024/05/24 | 1,050 | 1,067 | 1,024 | 1,037 | -13 | -1.2% | 28,000 |
| 2024/05/23 | 1,072 | 1,082 | 1,042 | 1,050 | -20 | -1.9% | 33,500 |
| 2024/05/22 | 1,143 | 1,143 | 1,070 | 1,070 | -61 | -5.4% | 40,100 |
| 2024/05/21 | 1,119 | 1,145 | 1,095 | 1,131 | +18 | +1.6% | 38,900 |
| 2024/05/20 | 1,069 | 1,139 | 1,062 | 1,113 | +33 | +3.1% | 40,400 |
| 2024/05/17 | 1,113 | 1,115 | 1,072 | 1,080 | -30 | -2.7% | 73,100 |
101～
150
件表示中 / 215件
類似銘柄と比較する
現在ご覧いただいている「ＶＩＳ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＶＩＳ | 69,500円 | -47.5% | - | 0.00% | - | 1.91倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| クリングル | 81,000円 | +240.0% | - | 0.00% | - | 2.64倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
| カルナバイオ | 27,900円 | -61.2% | - | 0.00% | - | 1.66倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| キッズバイオ | 10,400円 | - | - | 0.00% | - | 5.47倍 |
|
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞（ＳＨＥＤ）用いた再生医療に力 |
| 免疫生物 | 45,200円 | +13.4% | -4.0% | 0.00% | 36.60倍 | 3.15倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
市場注目の銘柄
チャート関連のコラム
